414 related articles for article (PubMed ID: 33740125)
1. Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Wu Z; Tao H; Zhang S; Wang X; Ma J; Li R; Liu Z; Wang J; Cui P; Chen S; Di H; Huang Z; Zheng X; Hu Y
Cancer Immunol Immunother; 2021 Oct; 70(10):2971-2980. PubMed ID: 33740125
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Xu Z; Li T; Hu X; Hao X; Xing P; Li J
Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
5. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
8. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
9. First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study.
Ye Z; Zhang Y; Chen J; Wang X; Hong Y; Zhao Q
Int Immunopharmacol; 2023 Jul; 120():110344. PubMed ID: 37245298
[TBL] [Abstract][Full Text] [Related]
10. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
[TBL] [Abstract][Full Text] [Related]
13. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
14. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
Petrelli F; Ghidini M; Ghidini A; Tomasello G
JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
[TBL] [Abstract][Full Text] [Related]
16. Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
Gu L; Du N; Jin Q; Li S; Xie L; Mo J; Shen Z; Mao D; Ji J; Khadaroo PA; Chen B
Crit Rev Oncol Hematol; 2020 Mar; 147():102888. PubMed ID: 32018126
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
18. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
19. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
